PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression - Wikidata - thesis-toulmin - TriplyDB

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

http://www.wikidata.org/entity/Q34761941

about

Resistant mechanisms to BRAF inhibitors in melanoma Other targeted drugs in melanoma Melanoma: oncogenic drivers and the immune system Regulation of Bim in Health and Disease Therapy for BRAFi-Resistant Melanomas: Is WNT5A the Answer?Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets The GIST of targeted therapy for malignant melanoma Toward a Molecular Classification of Colorectal Cancer: The Role of BRAF Pathways and therapeutic targets in melanoma Beyond BRAF: where next for melanoma therapy?Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.Elucidating distinct roles for NF1 in melanomagenesis Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition.The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes Putting the pieces together: How is the mitochondrial pathway of apoptosis regulated in cancer and chemotherapy?Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines Functional profiling of live melanoma samples using a novel automated platform From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma PI3K and cancer: lessons, challenges and opportunities Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.Enhancing the evaluation of PI3K inhibitors through 3D melanoma models.A functional screen identifies specific microRNAs capable of inhibiting human melanoma cell viability.Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer.PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.In vitro treatment of melanoma brain metastasis by simultaneously targeting the MAPK and PI3K signaling pathways.Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors.Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.Evaluating melanoma drug response and therapeutic escape with quantitative proteomics Targeting human apurinic/apyrimidinic endonuclease 1 (APE1) in phosphatase and tensin homolog (PTEN) deficient melanoma cells for personalized therapy.Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer.The MAPK pathway as an apoptosis enhancer in melanoma.

P2860

Q26739717-2927A3D8-9163-4ACC-9DD8-86DAE9A4D6D2 Q26775594-55D07F78-7A4D-44F1-9095-0D6A66D865BB Q26775598-F7B30B1D-01FD-4101-9788-1DE778A11E27 Q26781203-C799EE02-8BA0-4502-B64F-A1BC0910EFC8 Q26782222-E5683D25-835F-4451-82D8-B3D26D11EEDE Q26795735-89285678-4A39-4C9E-AC2F-1F2682E5D9AF Q26827092-613C7049-725D-499A-8E5C-18E61552D7CA Q26827212-06412866-002C-4D2C-A006-01AC508E4609 Q26865736-FF9D0268-4A41-4E7C-B10C-205E2F3B2E55 Q27006853-73A7F43F-EA8B-453B-86E6-A4A045A14931 Q27334924-5EA5B208-042A-4E0B-9F8A-C56F220D787E Q27851698-074504C5-0959-4B0A-B64E-28CA2855A11F Q27851952-B564DCB6-1EFD-47CE-9D31-74DBD0D2C75C Q27852401-1E94962C-EFF6-40E1-A16C-5F3082FCACC4 Q27852827-56880CBB-2095-4E28-9AF7-34ADFD53EF20 Q27853045-5282CEDC-8755-4132-B4A3-8AE750BB3B1A Q27853295-91C4B8CA-DD62-425C-A2B8-63C21187B3D9 Q28069018-90A204C2-633C-448B-B28E-6DDEA608401A Q28072745-9336D52E-702F-4020-990B-4556E0533263 Q28085240-D707A008-1160-4A8F-A3E8-26413ACF1B65 Q28468571-1E85DC78-6744-4B7A-B1DF-DEE54FDA3FC0 Q28477048-E9F4AEEC-159B-4A2B-B063-512A1876F4AE Q28484649-F5780ED6-F36C-4802-AF3A-1E85D8B8580D Q28533949-CB2F6C33-1DF0-46CC-BF94-EC7DA4082184 Q28536351-77C13807-C38B-48FF-8670-D5BBFFC71841 Q30080017-5C2FCB26-C74B-40BD-86EA-ECC0180135E5 Q30277902-2F19BCE3-E911-4264-A7E5-2353C33F93D2 Q30746265-4869D6EA-5FDE-4B5E-9009-03AEFE0A6698 Q31087541-5916B89F-4FDD-4DA6-BF27-DF97C4EEBEC8 Q33399049-D0C9CFA1-6149-4369-8412-47F7A43C45AA Q33605281-D21612B4-9EA3-4050-9039-39BBA3CEAA90 Q33688428-F747CF29-2873-4E35-944D-039D704C15D1 Q33755862-6EA04A03-635A-493F-B7CA-E8C2AB5A19A5 Q33784436-2618BAD8-42B1-41C0-9A98-42D74ADBEB72 Q33808166-42BC5AC9-0930-484A-9BBA-318E07AE8368 Q33830911-14C5FAF0-0DF4-4D47-BFDC-D8B7820BC967 Q33850665-BB6C28E4-6DEB-443E-9D66-6D9C92F9C7F3 Q33917630-8247D47E-3915-4C3C-BC75-34DC6C5D05E0 Q34100838-DD1DC271-7CD1-488D-96BC-5D3EB06D0D39 Q34104135-8FA9BA75-B62C-4BC3-9B6C-BE5D7A3D7AD0

P2860

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

http://www.wikidata.org/entity/Q34761941

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

name

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@ast

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@en

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@nl

type

label

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@ast

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@en

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@nl

prefLabel

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@ast

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@en

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@nl

P1433

Q34761941-BC52D259-CDEA-42DA-84ED-BD935D58C64F

P1476

Q34761941-8F99409A-5864-49D8-A3C3-960603F302CA

P2093

Q34761941-0E0C8BB8-EEDA-436B-A201-8A6268113885

Q34761941-11FC6332-DF2B-433F-99C5-C7DEA7F41D2C

Q34761941-2C36C92A-3D64-478A-9B64-9BEF0CA1B43F

Q34761941-41A860ED-9F23-46DF-A35F-F7474E8B3CA7

Q34761941-496D840D-7262-4CFD-A737-18016578F1E0

Q34761941-73B996C4-C942-4608-BA2A-2FA70B575A96

Q34761941-7FDE4193-7E4E-4E8C-818A-53F35D1612ED

Q34761941-90CB6546-D0D2-4508-8F9E-1BBD5390D40D

Q34761941-CB4FDC18-28D2-48BF-8EA6-17D668F43D9E

Q34761941-DD70563A-84E1-4E42-9B59-30B7AE2E552B

P2860

Q34761941-04658EB4-1B60-44C7-979D-A29C8551BBD7

Q34761941-058B8C17-CF14-4281-A752-C88BB01463AD

Q34761941-0D2065A9-40CC-46F4-B10B-9AE2C00365D3

Q34761941-0F7139F5-545E-47C7-8C9F-BF560027C151

Q34761941-0FB4541F-CE28-4D6D-B1C1-CB7E3BE26784

Q34761941-10AFA6AD-BF6E-4AF3-AE3C-33CEC50CB976

Q34761941-10BB2742-FBAE-489A-98E4-24938159CDD7

Q34761941-1AFB71B5-BB32-4F95-8E32-F0525C75B1B9

Q34761941-1B4DD6DC-D293-44D4-A85D-D65D94B13C79

Q34761941-2510FB29-7669-4617-80EA-E3F60EAA4A7A

P304

Q34761941-33116FBC-9774-4518-A544-2E953A1290EC

P31

Q34761941-0120A1B3-7A7E-40D0-A842-25ABA256A734

P356

Q34761941-78AAA661-482F-4EE5-B646-DF5ABC901423

P407

Q34761941-02C1070D-A46C-4F7B-889F-E326005EEF9B

P433

Q34761941-DF475286-82C9-4558-8240-F360255996E1

P478

Q34761941-5F2E0787-4595-4E35-B42A-AD3776281E46

P50

Q34761941-24A153DD-C6A9-4DDE-A325-136BF420D6D4

Q34761941-BF942CA7-6453-4FBD-BDD4-9B3FD40784C2

Q34761941-CBE36E64-490B-437C-9E75-C0BB8438E5EE

P577

Q34761941-58FB89FA-B498-4D4B-8FAC-1F31E424B7DF

P698

Q34761941-685C1C26-636F-46EF-A6FE-136888FD2E42

P932

Q34761941-80B5BB55-1966-4538-AB84-A56C3C47328D

P356

0008-5472.CAN-10-2954

P1433

Cancer Research

P1476

PTEN loss confers BRAF inhibit ...... suppression of BIM expression

@en

P2093

A Cecilia Munko

http://www.w3.org/2001/XMLSchema#string

Antoni Ribas

http://www.w3.org/2001/XMLSchema#string

Elizabeth Wood

http://www.w3.org/2001/XMLSchema#string

Ethan V Abel

http://www.w3.org/2001/XMLSchema#string

Inna V Fedorenko

http://www.w3.org/2001/XMLSchema#string

Jane L Messina

http://www.w3.org/2001/XMLSchema#string

John M Koomen

http://www.w3.org/2001/XMLSchema#string

Kim H T Paraiso

http://www.w3.org/2001/XMLSchema#string

Maurizia Dalla Palma

http://www.w3.org/2001/XMLSchema#string

Vernon K Sondak

http://www.w3.org/2001/XMLSchema#string

P2860

Bim: a novel member of the Bcl-2 family that promotes apoptosis

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway

Functional role and oncogene-regulated expression of the BH3-only factor Bmf in mammary epithelial anoikis and morphogenesis

Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

Mutations of the BRAF gene in human cancer

BOD (Bcl-2-related ovarian death gene) is an ovarian BH3 domain-containing proapoptotic Bcl-2 protein capable of dimerization with diverse antiapoptotic Bcl-2 members

FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines

P304

2750-2760

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-10-2954

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Katherine L Nathanson

Keiran S M Smalley

Alexander Anderson

P577

2011-02-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21317224

http://www.w3.org/2001/XMLSchema#string

P932

3070772

http://www.w3.org/2001/XMLSchema#string